Novavax [NVAX] vs Liquidia [LQDA] Detailed Stock Comparison
Novavax
NASDAQ
Loading...
Liquidia
NASDAQ
Loading...
TLDR: Quick Comparison Summary
Based on 19 vital metrics comparison: Novavax wins in 10 metrics, Liquidia wins in 8 metrics, with 0 ties. Novavax appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | Novavax | Liquidia | Better |
|---|---|---|---|
| P/E Ratio (TTM) | 4.27 | -13.51 | Liquidia |
| Price-to-Book Ratio | 40.82 | 126.72 | Novavax |
| Debt-to-Equity Ratio | 607.28 | 1,319.26 | Novavax |
| PEG Ratio | -0.11 | -0.42 | Liquidia |
| EV/EBITDA | 2.83 | -14.31 | Liquidia |
| Profit Margin (TTM) | 39.20% | 58.00% | Liquidia |
| Operating Margin (TTM) | 44.17% | -424.41% | Novavax |
| EBITDA Margin (TTM) | 44.17% | N/A | N/A |
| Return on Equity | 30.06% | -389.13% | Novavax |
| Return on Assets (TTM) | 14.52% | -39.74% | Novavax |
| Free Cash Flow (TTM) | $-101.90M | $-101.87M | Liquidia |
| 1-Year Return | -27.53% | 106.13% | Liquidia |
| Price-to-Sales Ratio (TTM) | 1.43 | 99.94 | Novavax |
| Enterprise Value | $1.15B | $1.96B | Liquidia |
| EV/Revenue Ratio | 1.07 | 101.34 | Novavax |
| Gross Profit Margin (TTM) | 93.59% | 83.06% | Novavax |
| Revenue per Share (TTM) | $7 | $0 | Novavax |
| Earnings per Share (Diluted) | $2.22 | $-1.82 | Novavax |
| Beta (Stock Volatility) | 2.75 | 0.16 | Liquidia |
Performance
News Sentiment
Key Stats
Valuation
Financials
Short Interest
Dividends
Novavax vs Liquidia Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Novavax | -4.02% | 5.95% | 17.46% | 37.37% | 38.84% | 5.95% |
| Liquidia | 1.92% | 0.26% | -18.30% | 83.61% | 83.91% | 88.93% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Novavax | -27.53% | -53.84% | -91.52% | -94.09% | -80.43% | -82.33% |
| Liquidia | 106.13% | 328.89% | 699.30% | 108.01% | 108.01% | 108.01% |
News Based Sentiment: Novavax vs Liquidia
Novavax
News based Sentiment: NEUTRAL
The month's developments show continued operational activity with the Sanofi partnership expansion, but the market capitalization indicates a moderate investor valuation. There are no overwhelmingly positive or negative signals, resulting in a neutral overall investment story.
Liquidia
News based Sentiment: MIXED
Liquidia is facing both opportunities and challenges this month. The potential expansion into the IPF market is a positive catalyst, but the ongoing patent litigation with United Therapeutics and bearish options trading activity introduce significant uncertainty. This creates a mixed investment narrative.
Performance & Financial Health Analysis: Novavax vs Liquidia
| Metric | NVAX | LQDA |
|---|---|---|
| Market Information | ||
| Market Cap | $1.54B | $1.93B |
| Market Cap Category | Small cap | Small cap |
| 10 Day Avg. Volume | 3,833,181 | 3,320,420 |
| 90 Day Avg. Volume | 5,069,927 | 2,676,227 |
| Last Close | $9.08 | $22.86 |
| 52 Week Range | $5.01 - $13.77 | $9.71 - $29.94 |
| % from 52W High | -34.06% | -23.65% |
| All-Time High | $331.68 (Feb 08, 2021) | $38.46 (Oct 08, 2018) |
| % from All-Time High | -97.26% | -40.56% |
| Growth Metrics | ||
| Quarterly Revenue Growth | -0.42% | 1.42% |
| Quarterly Earnings Growth | -0.34% | 1.42% |
| Financial Health | ||
| Profit Margin (TTM) | 0.39% | 0.58% |
| Operating Margin (TTM) | 0.44% | -4.24% |
| Return on Equity (TTM) | 0.30% | -3.89% |
| Debt to Equity (MRQ) | 607.28 | 1,319.26 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | $0.23 | $0.18 |
| Cash per Share (MRQ) | $3.77 | $2.01 |
| Operating Cash Flow (TTM) | $-630,940,992 | $-116,055,000 |
| Levered Free Cash Flow (TTM) | $-627,235,008 | $-71,345,000 |
| Dividends | ||
| Last 12-Month Dividend Yield | N/A | N/A |
| Last 12-Month Dividend | N/A | N/A |
Valuation & Enterprise Metrics Analysis: Novavax vs Liquidia
| Metric | NVAX | LQDA |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | 4.27 | -13.51 |
| Forward P/E | -59.19 | -14.38 |
| PEG Ratio | -0.11 | -0.42 |
| Price to Sales (TTM) | 1.43 | 99.94 |
| Price to Book (MRQ) | 40.82 | 126.72 |
| Market Capitalization | ||
| Market Capitalization | $1.54B | $1.93B |
| Enterprise Value | $1.15B | $1.96B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 1.07 | 101.34 |
| Enterprise to EBITDA | 2.83 | -14.31 |
| Risk & Other Metrics | ||
| Beta | 2.75 | 0.16 |
| Book Value per Share (MRQ) | $0.23 | $0.18 |
Financial Statements Comparison: Novavax vs Liquidia
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
| Metric (MRQ) | NVAX | LQDA |
|---|---|---|
| Revenue/Sales | $626.33M | $3.12M |
| Cost of Goods Sold | $14.12M | $1.52M |
| Gross Profit | $612.22M | $1.60M |
| Research & Development | $88.94M | $6.97M |
| Operating Income (EBIT) | $515.51M | $-35.43M |
| EBITDA | $533.91M | $-33.25M |
| Pre-Tax Income | $519.85M | $-38.37M |
| Income Tax | $1.20M | N/A |
| Net Income (Profit) | $518.65M | $-38.37M |
Balance Sheet & Liquidity Metrics (MRQ)
| Metric (MRQ) | NVAX | LQDA |
|---|---|---|
| Cash & Equivalents | $263.34M | $169.76M |
| Total Current Assets | $868.03M | $177.21M |
| Total Current Liabilities | $422.17M | $60.52M |
| Long-Term Debt | $223.18M | $109.66M |
| Total Shareholders Equity | $-75.64M | $49.71M |
| Retained Earnings | $-4.49B | $-595.76M |
| Property, Plant & Equipment | $291.03M | $11.49M |
Cash Flow Statement Comparison (MRQ)
| Metric (MRQ) | NVAX | LQDA |
|---|---|---|
| Operating Cash Flow | $-185.78M | $-26.68M |
| Capital Expenditures | N/A | $-330,000 |
| Free Cash Flow | $-187.10M | $-31.01M |
| Debt Repayment | $-2.20M | $-2.19M |
| Common Stock Repurchase | N/A | N/A |
Short Interest & Institutional Ownership Analysis
| Metric | NVAX | LQDA |
|---|---|---|
| Shares Short | 44.72M | 18.47M |
| Short Ratio | 6.40 | 7.92 |
| Short % of Float | 0.28% | 0.27% |
| Average Daily Volume (10 Day) | 3,833,181 | 3,320,420 |
| Average Daily Volume (90 Day) | 5,069,927 | 2,676,227 |
| Shares Outstanding | 160.42M | 84.68M |
| Float Shares | 136.72M | 60.86M |
| % Held by Insiders | 0.09% | 0.13% |
| % Held by Institutions | 0.59% | 0.71% |
Dividend Analysis & Yield Comparison: Novavax vs Liquidia
| Metric | NVAX | LQDA |
|---|---|---|
| Last 12-Month Dividend | N/A | N/A |
| Last 12-Month Dividend Yield | N/A | N/A |
| 3-Year Avg Annual Dividend | N/A | N/A |
| 3-Year Avg Dividend Yield | N/A | N/A |
| 3-Year Total Dividends | N/A | N/A |
| Ex-Dividend Date | N/A | N/A |